Carnegie has acted as exclusive financial adviser to Growth House Holding, a leading Nordic specialty and niche generic pharmaceutical company, in the divestment of the company to Orifarm Generics, which is part of the Orifarm Group, the largest parallel importer of medicinal products and the largest supplier of pharmaceutical products in Denmark.
Growth House is a highly successful developer, manufacturer and distributor of specialty and niche generic pharmaceuticals in the Nordic markets. The Company’s strong organic revenue and EBITDA growth will continue in the coming years due to a strong product portfolio and a solid pipeline of new products. The key to the Company’s successful development is the ability to identify new specialty and niche generics with limited competition and bring these to market quickly and with lower development costs than its competitors.